Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013 Aug;62(8):1335-45.
doi: 10.1007/s00262-013-1436-4. Epub 2013 May 18.

Gamma delta T cells are activated by polysaccharide K (PSK) and contribute to the anti-tumor effect of PSK

Affiliations

Gamma delta T cells are activated by polysaccharide K (PSK) and contribute to the anti-tumor effect of PSK

Carol Inatsuka et al. Cancer Immunol Immunother. 2013 Aug.

Abstract

Polysaccharide K (PSK) is a widely used mushroom extract that has shown anti-tumor and immunomodulatory effects in both preclinical and clinical studies. Therefore, it is important to understand the mechanism of actions of PSK. We recently reported that PSK can activate toll-like receptor 2 and enhances the function of NK cells. The current study was undertaken to study the effect of PSK on gamma delta (γδ) T cells, another important arm of the innate immunity. In vitro experiments using mouse splenocytes showed that γδ T cells produce IFN-γ after treatment with PSK and have up-regulated expression of CD25, CD69, and CD107a. To investigate whether the effect of PSK on γδ T cells is direct or indirect, purified γδ T cells were cultured either alone or together with bone marrow-derived DC in a co-culture or trans-well system and then stimulated with PSK. Results showed that direct cell-to-cell contact between γδ T cells and DC is required for optimal activation of γδ T cells. There was also reciprocal activation of DC by PSK-activated γδ T cells, as demonstrated by higher expression of costimulatory molecules and enhanced production of IL-12 by DC in the presence of γδ T cells. PSK can also co-stimulate γδ T cells with anti-TCR and anti-CD3 stimulation, in the absence of DC. Finally, in vivo treatment with PSK activates γδ T cells among the tumor infiltrating lymphocytes, and depleting γδ T cells during PSK treatment attenuated the anti-tumor effect of PSK. All together, these results demonstrated that γδ T cells are activated by PSK and contribute to the anti-tumor effect of PSK.

PubMed Disclaimer

Conflict of interest statement

The authors declare they have no conflict of interest.

Figures

Fig. 1
Fig. 1
Gamma delta T cells are activated by PSK to produce IFN-γ. a Dose–response of PSK-stimulated IFN-γ production by splenocytes. Shown are mean ± SD of IFN-γ levels in triplicate culture wells treated with serial dilutions of PSK for 48 h, as determined by ELISA. Similar results were obtained from three independent experiments. b Representative FACS dot plots showing intracellular staining of IFN-γ in NK cells, γδ T cells, or αβ T cells in splenocytes from neu-transgenic mice. Splenocytes were treated with PSK (100 μg/ml) for 48 h. Similar results were obtained from three independent experiments. c, d Expression of CD25 and CD69 on γδ T cells in PSK-treated splenocytes. Shown are representative overlay histograms. Gray histogram: control; empty histogram: PSK-treated γδ T cells. The bar graphs summarize the results from three independent experiments. *p < 0.05, **p < 0.01 by two-tailed Student’s t test
Fig. 2
Fig. 2
PSK induces CD107a degranulation in γδ T cells. a Representative histograms showing the percentages of CD107a+ γδ T cells in control and PSK-treated splenocytes. b Summary graph showing the percentages of CD107a+ cells among total γδ T cells. The bars represent mean ± sem of results from three independent experiments. ***p < 0.001 by Student’s t test
Fig. 3
Fig. 3
Direct contact between DC and γδ T cells is required for optimal activation of γδ T cells by PSK. a Representative overlay histograms and summary graphs showing CD25 expression in PSK-treated purified γδ T cells, γδ + DC co-culture, and γδ + DC trans-well culture. b Representative overlay histograms and summary graphs showing CD69 expression in PSK-treated purified γδ T cells, γδ + DC co-culture, and γδ + DC trans-well culture. Gray histogram: control; empty histogram: PSK-treated γδ T cells. c Dose-dependent induction of CD25 and CD69 on γδ T cells in γδ + DC co-culture. Black histogram: control; gray histogram: low-dose PSK (10 μg/ml); white histogram: high-dose PSK (100 μg/ml)
Fig. 4
Fig. 4
Direct contact between DC and γδ T cells is required for PSK-induced IFN-γ production. a Representative dot plots showing the expression of IFN-γ in control PBS- and PSK-treated γδ T cells in different culture systems: γδ T cell alone, γδ + DC trans-well culture, or γδ + DC co-culture. b Bar graph summarizing the percentage of IFN-γ+ γδ T cells in PBS- and PSK-treated γδ T cells in different culture systems. The graph summarizes the results from three independent experiments. c Bar graph summarizing the level of IFN-γ in PBS- and PSK-treated γδ T cells in different culture systems. The graph summarizes the results from three independent experiments. *p < 0.05, **p < 0.01, by two-tailed Student’s t test
Fig. 5
Fig. 5
Reciprocal activation of DC in the BMDC-γδ T cell co-culture leads to increased expression of co-stimulatory molecules and enhanced production of IL-12. BMDC and BMDC-γδ T cell co-culture were treated with PSK for 24 h, and the cells were harvested for FACS analysis of DC activation markers. The culture supernatant was analyzed for IL-12 using ELISA. a Expression of CD40 and CD86 in BMDC treated with control RPMI medium or PSK (10 or 100 μg/ml). Shaded histograms: DC alone culture; empty histograms: DC + γδ T cell co-culture. b, c The levels of IL-12p40 and IL-12p70 in control untreated DC or DC + γδ T cell co-culture (white columns) and PSK-treated DC or DC + γδ T cell co-culture (black columns). *p < 0.05, by two-tailed Student’s t test
Fig. 6
Fig. 6
PSK co-stimulates purified γδ T cells with anti-γδ TCR mAb or anti-CD3 mAb to produce IFN-γ. a Purified γδ T cells were cultured on anti-γδ TCR mAb-coated plates in the presence or absence of PSK (100 μg/ml). The presence of PSK resulted in higher production of IFN-γ, as measured by ELISA. The bar graph summarizes results from three independent experiments. b Purified γδ T cells were cultured on anti-CD3 mAb-coated plates in the presence or absence of PSK (100 μg/ml). The presence of PSK resulted in higher production of IFN-γ, as measured by ELISA. The bar graph summarizes results from three independent experiments. *p < 0.05, by two-tailed Student’s t test
Fig. 7
Fig. 7
In vivo PSK treatment activates γδ T cells in TIL, and γδ T cell contributes to the anti-tumor effect of PSK. a Intratumoral injection of PSK results in CD69 upregulation on γδ T cells in TIL, but not in spleen. Shown are representative overlay histograms of CD69 expression on γδ T cells in TIL or spleen from control PBS- and PSK-treated mice. Shaded histogram PBS-treated mice (control); empty histogram: PSK-treated mice. The summary bar graph shows the mean fluorescence intensity (MFI) of CD69 expression in γδ T cells (mean ± sem) in TIL and spleen in PBS or PSK group (n = 8 mice per group). *p < 0.05, by two-tailed Student’s t test. b Depletion of γδ T cells during PSK treatment decreased the anti-tumor effect of PSK. Mice received anti-γδ TCR mAb or a control hamster IgG during PSK treatment. PSK by itself significantly inhibited tumor growth, and the effect is significantly attenuated when mice received anti-γδ TCR mAb. **p < 0.01 between PSK + γδ T cell depletion group (filled triangle) and PSK group (open square); ***p < 0.0001 between control PBS (open circle) and PSK group (open square). There was no difference between PSK + control IgG (filled inverted triangle) and PSK group (open square). N = 5 mice per group. Similar results were obtained from two independent experiments

References

    1. Ernst E, Cassileth BR. The prevalence of complementary/alternative medicine in cancer: a systematic review. Cancer. 1998;83:777–782. doi: 10.1002/(SICI)1097-0142(19980815)83:4<777::AID-CNCR22>3.0.CO;2-O. - DOI - PubMed
    1. Cassileth BR, Vickers AJ. High prevalence of complementary and alternative medicine use among cancer patients: implications for research and clinical care. J Clin Oncol. 2005;23:2590–2592. doi: 10.1200/JCO.2005.11.922. - DOI - PubMed
    1. Hyodo I, Amano N, Eguchi K, Narabayashi M, Imanishi J, Hirai M, Nakano T, Takashima S. Nationwide survey on complementary and alternative medicine in cancer patients in Japan. J Clin Oncol. 2005;23:2645–2654. doi: 10.1200/JCO.2005.04.126. - DOI - PubMed
    1. Kidd PM. The use of mushroom glucans and proteoglycans in cancer treatment. Altern Med Rev. 2000;5:4–27. - PubMed
    1. Fisher M, Yang LX. Anticancer effects and mechanisms of polysaccharide-K (PSK): implications of cancer immunotherapy. Anticancer Res. 2002;22:1737–1754. - PubMed

Publication types

MeSH terms

LinkOut - more resources